ClinicalTrials.gg
RecruitingNCT07848815ELUCIDUpdated Sep 30, 2026

Risk-Based Lung Cancer Detection in COPD Patients

An interventional study of Risk-based prediction models in Lung Cancer (Diagnosis) and COPD (Chronic Obstructive Pulmonary Disease), sponsored by Vejle Hospital. Recruiting at 1 site in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Vejle Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Sep 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.

Planned enrollment
9th of 94
1,000 · median 158
Started
2026
with 9 others
No phase
46 of 124
14 open now
Primary completion
2027-12
later than 29 of 46 live
Registered
124th of 124
by date
Lead sponsor
7 of 124
Vejle Hospital

Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 9th largest by planned enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2026, is one of 46 with no phase, reaches primary completion later than 29 of the 46 other live ones, and was the 124th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Lung Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

The goal of the interventional study is to evaluate whether risk-based stratification using the PLCOm2012 model and a machine learning (ML) model can identify patients with chronic obstructive pulmonary disease (COPD) who are at high risk of developing lung cancer and may benefit from low-dose computed tomography (LDCT) screening. The study population includes adults aged 50 years and older with COPD and a history of smoking attending an outpatient clinic.

The main question it aims to answer are:

- What is the incidence of histopathologically confirmed lung cancer following risk-based stratification?

Participants will:

  • Undergo lung cancer risk assessment using the PLCOm2012 model and an ML-based model based on clinical and laboratory data
  • Be referred for LDCT if classified as high-risk
  • Continue standard care if classified as low-risk
  • Be followed through electronic health records for up to six years to assess outcomes including lung cancer incidence, adherence to LDCT, time to imaging, healthcare utilization, costs, and safety
Read the detailed description

Lung cancer is a leading cause of cancer-related mortality in Denmark, largely due to late-stage diagnosis. Early detection through low-dose computed tomography (LDCT) has been shown to reduce mortality in trials such as the National Lung Screening Trial and the NELSON trial, but implementation remains limited due to cost, capacity, and risk of false-positive findings. Risk-based approaches may improve screening efficiency by identifying individuals at highest risk.

This prospective, single-centre interventional study evaluates the feasibility and clinical implementation of lung cancer risk stratification in patients with chronic obstructive pulmonary disease (COPD). A total of 1,000 patients will be enrolled from an outpatient clinic. At baseline, participants will undergo risk assessment using the PLCOm2012 model and a machine learning (ML)-based model based on clinical and laboratory data.

Patients identified as high-risk by either model will be referred for LDCT, while low-risk patients will continue standard care. If LDCT findings are suspicious, further diagnostic evaluation will be performed according to routine clinical practice. Participants will be followed through electronic health records for up to six years, with outcome assessment at 1, 2, and 6 years.

The primary outcome is the incidence of histopathologically confirmed lung cancer. Secondary outcomes include adherence to LDCT referral, time from risk assessment to LDCT, number needed to screen, healthcare utilization, healthcare costs, and safety, including adverse events related to diagnostic procedures.

03

Conditions studied

  • Lung Cancer (Diagnosis)
  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • Lung cancer
  • Chronic obstructive pulmonary disease
  • Machine learning
  • Prediction models
  • Biomarkers
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with
  • Age ≥ 50 years
  • Attendance at the outpatient Respiratory Medicine clinic, Vejle Hospital, University Hospital of Southern Denmark
  • Smoking history (current or former smoker)
  • Consent to translational research and biobank.

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of lung cancer within the last five years.
  • Active treatment for cancer within the last 12 months except non-melanoma skin cancer and carcinoma in situ cervicis uteri.
  • Invasive methods to verify potential lung cancer not an option.
  • Inability to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    COPD patients undergoing lung cancer risk assessment

    All enrolled patients with chronic obstructive pulmonary disease (COPD) will undergo lung cancer risk assessment using the PLCOm2012 model and an in-house developed machine learning model. Based on the model-derived risk score, patients will be stratified into high-risk and low-risk groups. Patients classified as high-risk will undergo further diagnostic evaluation for lung cancer according to the study protocol. Patients classified as low-risk will continue with standard of care management. Outcomes will be compared between risk groups to evaluate the feasibility and clinical utility of the model.

    Other: Risk-based prediction models

Interventions

  • OtherRisk-based prediction models

    Patients will be stratified into high-risk and low-risk groups using both the Lung Cancer Risk Prediction Calculator for smokers (PLCOm2012) and an in-house developed machine learning model based on sex, age, smoking status, and laboratory data from routine blood sample analyses.

06

What researchers measure

Primary outcomes

  1. Number of histopathologically confirmed lung cancers

    Time frame: From risk assessment to end of follow-up at 6 years

Secondary outcomes

  1. Proportion of high-risk patients who undergo LDCT after referral

    Time frame: From risk assessment to LDCT completion at 1 year

  2. Number of COPD patients requiring risk assessment and LDCT screening to detect one case of lung cancer

    Time frame: From risk assessment to end of follow-up at 6 years

  3. Time from risk assessment to completion of LDCT

    Time frame: From risk assessment to LDCT completion at 1 year

  4. Number of diagnostic procedures per patient stratified by risk group

    Time frame: From risk assessment to end of follow-up at 6 years

  5. Number of hospitalizations per patient stratified by risk group

    Time frame: From risk assessment to end of follow-up at 6 years

  6. Number of outpatient visits per patient stratified by risk group

    Time frame: From risk assessment to end of follow-up at 6 years

  7. Healthcare costs per detected lung cancer case stratified by risk group

    Time frame: From risk assessment to end of follow-up at 6 years

  8. Healthcare costs per patient stratified by risk group

    Time frame: From risk assessment to end of follow-up at 6 years

  9. Proportion of eligible COPD patients consenting to risk assessment

    Time frame: From risk assessment to end of follow-up at 6 years

  10. Proportion of eligible COPD patients completing LDCT

    Time frame: From risk assessment to LDCT completion at 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bang Henriksen M, Hansen TF, Jensen LH, Brasen CL, Borg M, Hilberg O, Lokke A. Lung cancer among outpatients with COPD: a 7-year cohort study. ERJ Open Res. 2024 Jul 22;10(4):00064-2024. doi: 10.1183/23120541.00064-2024. eCollection 2024 Jul. PubMed 39040576 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 865 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 68. This study's planned 18 months is below that.

Counting every sponsor, half of 916 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2033
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848815
Lead sponsor
Vejle Hospital
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Jun 1, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2033 (estimated)
Last update
Sep 30, 2026

Study contacts

Cecilie M. Jacobsen, MScEng
Contact
cecilie.mondrup.jacobsen@rsyd.dk
+4579406644
Morten H. Borg, MD, PhD
study director · Vejle Hospital, University Hospital of Southern Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion